SAN FRANCISCO–(BUSINESS WIRE)– Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP- 002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options.
Immusoft’s Immune System Programming (ISP™) technology platform has been designed to address the challenges associated with current cell therapies
Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.
– Two presentations to highlight the transposon-engineered B lymphocytes ISP™ platform for MPS I and enhancement of muscle mass – Seattle, Wash.–(BUSINESS WIRE) –May 12, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced two upcoming virtual oral presentations at the ASGCT 23rd Annual…
– Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform – Seattle, Wash.–(BUSINESS WIRE) –February 5, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced that Scott McIvor, Ph.D., Chief Development Officer, and Professor Genetics, Cell Biology, and…
Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform
Seattle, Wash.–(BUSINESS WIRE) –July17,2019–Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced the appointment of Robert Hayes, Ph.D., as Chief Scientific Officer. With nearly two decades of biologics discovery and development experience, Dr. Hayes will lead Immusoft’s preclinical research and spearhead the near-term advancement…
Seattle, Wash.–(BUSINESS WIRE) –January 3, 2019– Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today it has held the final closing in its $20 million oversubscribed Series B financing. Immusoft plans to use the proceeds from this financing to advance ISP-001 (iduronicrin genleukocel-T) through Phase I/II…
